🇺🇸 FDA
Patent

US 9211289

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

granted A61KA61K31/194A61K31/4468

Quick answer

US patent 9211289 (Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases) held by ACADIA Pharmaceuticals Inc. expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/194, A61K31/4468, A61K45/06, A61K9/20